Spotlight Report on Endometriosis Market 2021: Treatments, Epidemiology, Drugs Marketed, Drugs in Development, Revenue Opportunities, Clinical Trials – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Endometriosis” report has been added to from ResearchAndMarkets.com offer.

Endometriosis is an estrogen-dependent condition that affects approximately 10% of women of childbearing age and can lead to chronic pelvic pain, infertility, or both. It is estimated that endometriosis is present in 24-50% of infertile women and in more than 20% of those with chronic pelvic pain. Information collected by the American Congress of Obstetricians and Gynecologists indicates that in approximately 60% of adult patients with endometriosis, symptoms begin before the age of 20.

Key points to remember

  • The publisher estimated that in 2019, there were 191.0 million prevalent cases of endometriosis in women aged 15-49 worldwide, and projects that number will rise to 201.8 million prevalent cases. by 2028.

  • Endometriosis affects approximately one in 10 women in the reproductive age group of 15 to 49 years. Drugs approved for endometriosis target gonadotropin-releasing hormone (GnRH) receptor, progesterone receptor, follicle-stimulating hormone (FSH), gonadotropin-releasing hormone (GnRH ) and androgen receptors. Majority of the marketed drugs are administered subcutaneously, while the rest are oral and intramuscular formulations.

  • The majority of industry-sponsored drugs in active clinical development for endometriosis are in Phase II, with two drugs in Phase III.

  • Therapies being developed for endometriosis focus on targets such as the gonadotropin-releasing hormone (GnRH) receptor, progesterone receptor, luteinizing hormone receptor (LHR), receptors to androgens and follicle-stimulating hormone (FSH). The majority of drugs in development are administered orally, with only one product being tested as a topical formulation.

  • Upcoming high-impact events for endometriosis drugs include key Phase III trial results for Trelstar and Yselty. The overall probability of approval of a Phase I gynecological asset is 11.9%, and the average probability of a drug progressing from Phase III is 70%. Drugs, on average, take 11.8 years from Phase I to approval, compared to 13.0 years across the obstetrics/gynecology space as a whole.

  • The distribution of clinical trials in phases I-IV indicates that the majority of endometriosis trials are in the early and middle phases of development, with 73% of trials in phase I-II and only 27% in phase III- IV. .

  • The United States has a substantial lead in the number of endometriosis clinical trials worldwide. Germany leads the major European markets, while Japan takes first place in Asia.

  • Clinical trial activity in the area of ​​endometriosis is dominated by completed trials. Bayer has the most completed clinical trials for endometriosis, with 45 trials.

  • Bayer leads the industry sponsors with the largest overall number of endometriosis clinical trials, followed by AbbVie and Takeda.

Main topics covered:

PREVIEW

KEY POINTS TO REMEMBER

DISEASE CONTEXT

PROCESSING

  • GnRH analogs

  • Progestins

  • Combined oral contraceptives

  • Nonsteroidal anti-inflammatory drugs

  • Danocrine

  • Operation

EPIDEMIOLOGY

MARKETED MEDICINES

CURRENT MEDICATIONS

RECENT EVENTS AND ANALYST VIEWS

  • Orgovyx for endometriosis (January 26, 2021)

  • Orgovyx for endometriosis (June 23, 2020)

  • Orgovyx for endometriosis (April 22, 2020)

MAIN UPCOMING EVENTS

LIKELIHOOD OF SUCCESS

GRANTS OF LICENSES AND ACQUISITION OF ASSETS

  • Genexine, Turret Capital Ink license for immunosuppressant

INCOME OPPORTUNITY

CLINICAL TRIALS LANDSCAPE

  • Sponsors by status

  • Sponsors per phase

BIBLIOGRAPHY

APPENDIX

For more information on this report, visit https://www.researchandmarkets.com/r/22fm25

Sallie R. Loera